Gene therapy injection aims to treat dry AMD
Disease control
Completed
This study tests the safety of a single injection of PST-611, a DNA-based therapy, in people aged 50 and older with dry age-related macular degeneration (AMD). The therapy is designed to make the eye produce a protein that may protect against vision loss. Participants receive one…
Phase: PHASE1 • Sponsor: Eyevensys • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC